HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)
HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)
HC Wainwright & Co. 維持買入評級,將目標股價調整爲$57(進行1-20股票回撥)rigel pharmaceuticals
HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy, adjusts target to $57 from $15 (1-20 Reverse Stock Split).
HC Wainwright & Co. 分析師Joseph Pantginis維持Rigel Pharmaceuticals (納斯達克:rigel pharmaceuticals)的買入評級,將目標價從15美元調整至57美元(1-20股票拆分)。